 By John Vandermosten, CFA NYSE:CVM CEL-SCI Corporation NYSE:CVM announced on May 4, 2020 that it had achieved the targeted number of events for its IT MATTERS trial for head and neck cancer. The trial enrolled its first patients in 2011 in the US, Canada, UK, France and 20 other countries. The primary endpoint for the study is an overall survival benefit of 10 over standard of care alone in 